Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel

http://advancedgastroonline.com/tag/fiber/ SAN FRANCISCO and TEL AVIV, Israel, Dec. 22, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”) today announced that the TSX Venture Exchange (“TSXV”) has approved the arrangement reached with The Salzman Group of Israel to allow Kalytera, at its option, to pay invoices under a services agreement with The Salzman Group in common shares of the Company (“Common Shares”). As previously announced on December 7, 2017, Kalytera has entered into a services agreement with The Salzman Group (the “Agreement”), under which The Salzman Group will provide clinical study management services  in relation to the Phase 2 study, including chemistry, manufacturing and controls (“CMC”) analytics, as well as stability studies, toxicology studies and drug-drug interaction studies, all of which will be required by the FDA to be completed prior to initiation of a Phase 3 pivotal study.